Abstract YO31
Case summary
A 66-year-old male presented with left-sided pleuritic chest pain, common weak for 2 months and progressively increasing shortness of breath with dry cough for 1.5 months.On general survey, mild pallor was present, but there were no clubbing and palpable cervical and axillary lymph node. An X-ray showed a shadow in the left chest. The shadow of the heart was shifted to the right. Bronchoscopy showed compression of segmental bronchus of the left upper lobe bronchus. CT of the chest reveals a nodular pleura-based mass, which size was about 12.5х18.0х18.0 sm with effusion in the left pleural cavity. Around the nodular pleura-based mass were infiltrative changens. The histological analysis of tru-cut biopsy showed that there was fibrotic mesothelioma with necrosis or carcinoid. The patient underwent right upper lobectomy of lung with negative margins. During operation we saw that half of left pleural cavity was occupied by gigantic tumor, which size was 25x20x18 sm. Surface was bumpy, it had capsule, thick texture. There were effusion (150ml) in the left pleural cavity. The root of the lung, pericardium, thoracic part of aorta, diaphragm were free. The tumor was grew from right upper lobe (S5). The histological analysis after operation of this tumor showed that it was round cell sarcoma. After surgery, six cycles of adjuvant chemotherapy with ifosfamide and doxorubicin were given. Postadjuvant chemotherapy patient is kept on regular follow-up.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract